|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZHX1 |
Gene summary for ZHX1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZHX1 | Gene ID | 11244 |
| Gene name | zinc fingers and homeoboxes 1 | |
| Gene Alias | ZHX1 | |
| Cytomap | 8q24.13 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | A0A024R9F1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11244 | ZHX1 | LZE4T | Human | Esophagus | ESCC | 8.05e-10 | 3.24e-01 | 0.0811 |
| 11244 | ZHX1 | LZE7T | Human | Esophagus | ESCC | 1.74e-07 | 3.45e-01 | 0.0667 |
| 11244 | ZHX1 | LZE20T | Human | Esophagus | ESCC | 2.23e-08 | 1.65e-01 | 0.0662 |
| 11244 | ZHX1 | LZE24T | Human | Esophagus | ESCC | 2.95e-12 | 5.12e-01 | 0.0596 |
| 11244 | ZHX1 | P2T-E | Human | Esophagus | ESCC | 5.80e-21 | 3.37e-01 | 0.1177 |
| 11244 | ZHX1 | P4T-E | Human | Esophagus | ESCC | 6.54e-24 | 5.37e-01 | 0.1323 |
| 11244 | ZHX1 | P5T-E | Human | Esophagus | ESCC | 1.65e-19 | 2.87e-01 | 0.1327 |
| 11244 | ZHX1 | P8T-E | Human | Esophagus | ESCC | 8.97e-16 | 1.90e-01 | 0.0889 |
| 11244 | ZHX1 | P9T-E | Human | Esophagus | ESCC | 2.23e-13 | 2.79e-01 | 0.1131 |
| 11244 | ZHX1 | P10T-E | Human | Esophagus | ESCC | 6.82e-14 | 3.54e-01 | 0.116 |
| 11244 | ZHX1 | P11T-E | Human | Esophagus | ESCC | 1.15e-09 | 3.74e-01 | 0.1426 |
| 11244 | ZHX1 | P12T-E | Human | Esophagus | ESCC | 8.24e-16 | 3.93e-01 | 0.1122 |
| 11244 | ZHX1 | P15T-E | Human | Esophagus | ESCC | 2.91e-12 | 2.19e-01 | 0.1149 |
| 11244 | ZHX1 | P16T-E | Human | Esophagus | ESCC | 2.67e-39 | 7.51e-01 | 0.1153 |
| 11244 | ZHX1 | P17T-E | Human | Esophagus | ESCC | 8.76e-07 | 3.53e-01 | 0.1278 |
| 11244 | ZHX1 | P20T-E | Human | Esophagus | ESCC | 6.00e-21 | 4.87e-01 | 0.1124 |
| 11244 | ZHX1 | P21T-E | Human | Esophagus | ESCC | 5.23e-25 | 5.49e-01 | 0.1617 |
| 11244 | ZHX1 | P22T-E | Human | Esophagus | ESCC | 1.63e-16 | 3.28e-01 | 0.1236 |
| 11244 | ZHX1 | P23T-E | Human | Esophagus | ESCC | 3.23e-22 | 6.85e-01 | 0.108 |
| 11244 | ZHX1 | P24T-E | Human | Esophagus | ESCC | 1.25e-15 | 3.00e-01 | 0.1287 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZHX1 | SNV | Missense_Mutation | c.1402N>T | p.Arg468Trp | p.R468W | Q9UKY1 | protein_coding | deleterious(0) | probably_damaging(0.97) | TCGA-A8-A07B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZHX1 | SNV | Missense_Mutation | c.1342N>T | p.Pro448Ser | p.P448S | Q9UKY1 | protein_coding | tolerated(0.06) | benign(0.015) | TCGA-D8-A142-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cyclophosphamid | SD | |
| ZHX1 | SNV | Missense_Mutation | c.512T>C | p.Val171Ala | p.V171A | Q9UKY1 | protein_coding | tolerated(0.85) | benign(0) | TCGA-EW-A1IZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxotere | SD | |
| ZHX1 | insertion | Frame_Shift_Ins | novel | c.882_883insGTTCATCAAC | p.Asn295ValfsTer10 | p.N295Vfs*10 | Q9UKY1 | protein_coding | TCGA-AN-A0FW-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| ZHX1 | insertion | Frame_Shift_Ins | novel | c.2333_2334insAA | p.Phe778LeufsTer14 | p.F778Lfs*14 | Q9UKY1 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | ||
| ZHX1 | insertion | Nonsense_Mutation | novel | c.2332_2333insAATAATTAAGACATTAAACTCTACATAATAA | p.Phe778Ter | p.F778* | Q9UKY1 | protein_coding | TCGA-AR-A0TU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Doxorubicin | SD | ||
| ZHX1 | insertion | In_Frame_Ins | novel | c.2541_2543dupGGA | p.Glu847dup | p.E847dup | Q9UKY1 | protein_coding | TCGA-GM-A2DA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | PD | ||
| ZHX1 | SNV | Missense_Mutation | novel | c.1159N>G | p.Thr387Ala | p.T387A | Q9UKY1 | protein_coding | deleterious(0) | possibly_damaging(0.458) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ZHX1 | SNV | Missense_Mutation | rs754988142 | c.145N>A | p.Asp49Asn | p.D49N | Q9UKY1 | protein_coding | deleterious(0.03) | benign(0.022) | TCGA-C5-A3HE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| ZHX1 | SNV | Missense_Mutation | c.549N>G | p.Ile183Met | p.I183M | Q9UKY1 | protein_coding | tolerated(0.05) | probably_damaging(0.997) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |